NATALIZUMAB HIGH TITER

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是评价复发型MS受试者静脉给予那他珠单抗高滴度材料的免疫原性。本研究的次要目的是评价那他珠单抗高滴度材料的安全性

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to evaluate the immunogenicity of natalizumab high titer material administered intravenously to subjects with relapsing forms of MS. The secondary objective of this study is to evaluate the safety of natalizumab high titer material